Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/582
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHurley, James C.en
dc.date.accessioned2014-09-01T06:10:04Zen
dc.date.available2014-09-01T06:10:04Zen
dc.date.issued2013en
dc.identifier.govdoc00514en
dc.identifier.issn2072-6651en
dc.identifier.urihttp://hdl.handle.net/11054/582en
dc.description.abstractEndotoxin is a potent mediator of a broad range of path-physiological effects in humans and present in all Gram negative (GN) bacteria. It would be expected that anti-endotoxin therapies, antibody based or not, would play an important adjuvant therapeutic role along with antibiotics and other supportive therapies for GN infections. There is an extensive literature relating to pre-clinical and clinical studies of anti-endotoxin antibodies however there is a unknown and unexplained disconnect between generally successful pre-clinical studies versus the failures of the many large clinical trials of antibody based and other anti-endotoxin therapies. This disconnect is not merely an abstract academic question as there are ongoing clinical trials of interventions to reduce levels of endotoxemia levels. The aim of this review is to examine new insights into the complex relationship between endotoxemia and sepsis in an attempt to bridge this disconnect. New factors to consider in this reappriasal include the frequency and types of GN bateremia and the underlying mortality risk in the different study populations. Endoxemia can no longer be considered a single entity for a range of reasons. Old clinical trials warrant a re-appraisal in light of recent advances in the understanding of the structure-fuction relationship of endotoxin. The disconnect not only remains however, it has enlarged.en
dc.description.provenanceSubmitted by Gemma Siemensma (gemmas@bhs.org.au) on 2014-04-07T01:55:41Z No. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2014-09-01T06:10:04Z (GMT) No. of bitstreams: 1 toxins-05-02589[1].pdf: 472757 bytes, checksum: c3ec2792e4a26b8e0a04cf729455c10f (MD5)en
dc.description.provenanceMade available in DSpace on 2014-09-01T06:10:04Z (GMT). No. of bitstreams: 1 toxins-05-02589[1].pdf: 472757 bytes, checksum: c3ec2792e4a26b8e0a04cf729455c10f (MD5) Previous issue date: 2013en
dc.publisherMDPI AGen
dc.titleTowards clinical applications of anti-endotoxin antibodies; a re-appraisal of the disconnect.en
dc.typeJournal Articleen
dc.type.specifiedArticleen
dc.bibliographicCitation.titleToxinsen
dc.bibliographicCitation.volume5en
dc.bibliographicCitation.stpage2589en
dc.bibliographicCitation.endpage2620en
dc.publisher.placeBasel, Switzerlanden
dc.subject.healththesaurusBACTERIAL TOXINSen
dc.subject.healththesaurusGRAM-NEGATIVE BACTERIAen
dc.subject.healththesaurusANTI-BACTERIAL AGENTSen
dc.subject.healththesaurusANTI-ENDOTOXIN ANTIBODIESen
dc.subject.healththesaurusENDOTOXINSen
dc.subject.healththesaurusENDOTOXINen
dc.subject.healththesaurusENDOTOXEMIAen
dc.subject.healththesaurusSEPSISen
dc.subject.healththesaurusPOLYMYXINen
dc.date.issuedbrowse2013-01-01en
Appears in Collections:Research Output

Files in This Item:
File Description SizeFormat  
toxins-05-02589[1].pdfToxins article461.68 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.